Shattuck Labs Inc 2026年季度报告

SHATTUCK LABS, INC.TABLE OF CONTENTS PART IFINANCIAL INFORMATION1Item 1.Condensed Financial Statements (Unaudited)1Condensed Balance Sheets asof March31, 2026 and December31, 20251Condensed Statements of Operations and Comprehensive Loss for the Three Months EndedMarch31, 2026 and20252Condensed Statements of Changes in Stockholders’ Equity for the Three Months EndedMarch31, 2026 and 20253Condensed Statements of Cash Flows for the Three Months Ended March31, 2026 and 20254Notes to the Unaudited Interim Condensed Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk28Item 4.Controls and Procedures28PART IIOTHER INFORMATION29Item 1.Legal Proceedings29Item 1A.Risk Factors29Item 2.Unregistered Sales of Equity Securities and Use of Proceeds29Item 3.Defaults Upon Senior Securities29Item 4.Mine Safety Disclosures29Item 5.Other Information29Item6.Exhibits30Signatures31 CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, whichstatements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other thanstatements of historical facts, including statements concerning our plans, objectives, goals, strategies, future events, future revenues orperformance, financing needs, plans or intentions relating to products and markets, and business trends and other information referred tounder the sections entitled “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,”are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,”“objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,”“develop,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Forward-lookingstatements are not historical facts, and reflect our current views with respect to future events, outcomes or results. Given the significant risksand uncertainties, you should not place undue reliance on these forward-looking statements. There are a number of risks, uncertainties and other factors that could cause our actual results or outcomes, or the timing of our resultsor outcomes, to differ materially from the forward-looking statements expressed or implied in this Quarterly Report on Form 10-Q. Suchrisks, uncertainties and other factors include, among others, the following: • the timing of the initiation, progress, and expected results of our nonclinical studies, our clinical trials, and our research anddevelopment programs;• our ability to enroll patients in our clinical trials;• the costs related to our nonclinical studies, our clinical trials, our research and development programs, and the impact of inflationarypressures on such costs;• our ability to retain the continued service of our key executives and to identify, hire, and retain additional qualified professionals;• our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical trials;• the timing or likelihood of regulatory filings and approvals;• the commercialization of our product candidates, if approved;• our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use,if approved;• the pricing, coverage, and reimbursement of our product candidates, if approved;• the implementation of our business model, strategic plans for our business, and product candidates;• the scope of protection we are able to establish and maintain for intellectual property rights covering our technology;• our potential need to obtain additional licenses of third-party technology that may not be available to us or are available only oncommercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner thatwas not anticipated;• our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of such arrangements;• our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;• our estimates regarding the market opportunity for our product candidates, if approved;• our estimates regarding expenses, capital requirements, and needs for additional financing and our ability to obtain additional capital;• our financial performance; • developments relating to our competitors and our industry, including competing product candidates and therapies; and • economic downturns, inflation, fluctuating interest rates, changes in trade policies, including tariffs or other trade restrictions or thethreat of such actions, natural disasters, pub